Minutes: Steering Board meeting, 23 December 2020

1. Implementation of contracts

Generally, the Members were drawn the attention to the fact that until the end of the year this would need to be finalized as soon as possible, ideally by the end of the day.

The Members were also reminded that while the five-day opt-out expires, each of the Member States is contractually bound by its pro-rata attribution.

Pfizer/BioNTech:
- the Members were informed about:
  - the company's indicative timetable for the delivery of the optional doses: based upon approval in of a new plant, they plan to deliver doses in 2021 and doses of the dose option in 2021;
  - the company stressed that it would be difficult to doses in 2021 based upon the existing capacity utilization of plants;
- the allocation table was discussed at length with a tour de table;
- after an in depth discussion, the SB decided to inform the company about Member States' interest for the total amount of the optional doses:
- all Member States were encouraged to provide feedback/confirmation as regards their interest for optional doses because the company would need to be informed as soon as possible to secure the doses;
- those Members who have not yet send the filled and signed Vaccine Order Form to the EC Vaccines mailbox as soon as possible, as they need to reach the company by
Moderna:
- those Members who have not yet sent the filled and signed Vaccine Order Form to the EC Vaccines mailbox should do so as soon as possible and at the latest by [redacted];
- if MSs requested both initial and optional Doses, as reflected in the allocation table, they were requested to prepare two separate Vaccine Order Forms;

The Commission organized a meeting with the representatives of the company and the Steering Board members to explain elements related to medical information, logistics, regulatory aspects etc, The PPT will be distributed via a secured transmission.

Curevac
- [redacted] a number of doses still need to be attributed to Members States;
- more work would be needed on the final volumes. The Commission recalled that after the five-day opt-out expires, each of the Member States is contractually bound by its pro-rata attribution.
- the [underlined] that in the current context it would be easy for Member States [redacted], the EU could show its solidarity with the rest of the world, and Member States could help other countries with doses [redacted];
- Commission clarified that it did not [redacted] buy itself the doses that were still not appropriated by Member States;
- Members were asked to provide feedback to complete the allocation by [redacted].

Janssen
- Members were informed that most of the Vaccine Order Forms were received but were encouraged to submit by [redacted] the missing ones [redacted] that were highlighted by the Commission;

2. Update on contracts and discussions with other companies

Novavax - the Members were informed that [redacted]

Valneva -the Members were informed of the Commission’s intention to proceed to [redacted].
3. COVAX

An in-depth discussion was carried on COVAX, on the high need and demand on vaccines in the rest of the world and the common approach on donations that would allow EU to help from its secured contractual vaccines portfolio.

COVAX’s position was outlined in securing vaccine doses.

It was also outlined that:

- there was a big demand for donations and resale internationally;
- the MSs could look for a contribution to COVAX but unlike the EU,
- it was very important that the MSs decide the number of doses that each would like to resell/donate and consequently to make this info public to allow interested countries to express their interest as soon as possible;
- the MSs could look for